The EMMY trial highlights ameliorating effects of SGLT2-inhibition after AMI by significantly reducing NTproBNP levels and showing significant effects on structural and functional cardiac parameters, however DAPA-MI as well as EMPACT-MI failed to show significant difference concerning hospitalisation from heart failure and all-cause death and thus, further research in this area must be performed. The gene discussed is NPPB; the disease is heart failure.